Home
Search
Search Results
Previously Searched
3124 results found
Expand All
Apply All
3124 results found

Good Day BIO: EU and Japan show how drug price controls stifle biotech
Good Day BIO Newsletter  •  August 3, 2022
With Senate Democrats scrambling to pass drug price controls before the recess, we look at the experiences of the EU and Japan with price controls and the impact on innovation. ICYMI, monkeypox cases are rising—we look at the current state and what it tells us about future preparedness. (829 words, 4 minutes, 8 seconds)
Read More

BIO Applauds Senator Tom Tillis for Introducing the Patent Eligibility Restoration Act
Human Health  •  Letters, Testimony & Comments  •  August 2, 2022
On behalf of the Biotechnology Innovation Organization, I want to thank you for introducing the Patent Eligibility Restoration Act. This important legislation will bring much-needed and overdue clarity to Section 101 of the Patent Act. The existing uncertainty in the law has been a major impediment to the cutting-edge work of our innovators. 
Read More

Good Day BIO: Price controls will harm the economy – here's why
Good Day BIO Newsletter  •  August 2, 2022
Drug price controls would not only kill future cures—but would also harm the economy, several new studies say. Plus, the pandemic might have curbed greenhouse gas emissions (for a time), but it led to a resurgence of the plastic problem. Enter biotech, which is developing sustainable alternatives to single-use plastic. (753 words, 3 minutes, 45 seconds)
Read More

Good Day BIO: Price controls would 'devastate' medical innovation
Good Day BIO Newsletter  •  August 1, 2022
A new week, a new month—and the last week the Senate’s in session before the August recess. We’ll be keeping an eye on what happens with the “slimmed down” Build Back Better, which includes anti-science drug price controls. Meanwhile, we’re worried about the heat—but we should also be worried about soil, says the UN. (651 words, 3 minutes, 15 seconds)
Read More

CSBA Sends Letter to Congressional Leadership on Negative Impacts of Democrats' Drug Pricing Proposal
Human Health, Council for State Biotechnology Associations (CSBA)  •  Letters, Testimony & Comments  •  July 29, 2022
The Council of State Bioscience Associations (CSBA) is an alliance of independent, state and territory based, non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative life-enhancing and life-saving biotechnology solutions. We write today to express our serious concerns about the proposals included in the recently released Senate Democrats’ drug pricing proposals, which will devastate that innovation. Most of our biopharmaceutical member companies are small-to-medium in size and relatively few have products on the market. Yet, these companies are leading the world in cutting edge research to develop new therapies and cures, including gene and cell therapies, and of course, vaccines and treatments for COVID-19.
Read More

Good Day BIO: New study says price controls devastate drug R&D, patient access
Good Day BIO Newsletter  •  July 29, 2022
With drug price controls under consideration in the Senate, new analysis shows how they would devastate drug development and new treatments. On World Hepatitis Day, we look at why this preventable, treatable virus is still a threat. (740 words, 3 minutes, 42 seconds) P.S. The BIO Impact Agriculture & Environment conference is right around the corner. Be sure to register today.
Read More

Good Day BIO: USTR nominee would use ‘every tool’ to enforce USMCA biotech provisions
Good Day BIO Newsletter  •  July 28, 2022
Ending the week with what USTR nominee Doug McKalip said about agricultural biotech trade with Mexico and Korea, plus a new report that shows the dire need to invest in public health infrastructure and preparedness. (783 words, 3 minutes, 54 seconds)
Read More

Good Day BIO: State Medicaid policies can interfere with access to new treatments, says report
Good Day BIO Newsletter  •  July 27, 2022
A new report finds the patchwork of state regulations regarding Medicaid coverage for new, innovative treatments can create barriers for patients seeking access to the most advanced therapies. Meanwhile, it’s getting hotter on Earth—and biotech is helping us explore new possibilities for growing food in space. (774 words, 3 minutes, 52 seconds)
Read More

Good Day BIO: Why we need to focus on the value of care
Good Day BIO Newsletter  •  July 26, 2022
With everyone talking about drug pricing, we have an exclusive look at why we need to think about value rather than cost. Plus, we’re celebrating Dr. Rosalind Franklin’s birthday—and looking for the next biotech game-changers. (699 words, 3 minutes, 29 seconds)
Read More

Good Day BIO: WHO declares monkeypox a 'health emergency'
Good Day BIO Newsletter  •  July 25, 2022
Over the weekend, WHO declared monkeypox a health emergency of international concern—we tell you what that means and what’s happening in the U.S. Plus, recent CBO analysis of proposed drug price controls misinforms—and misses the mark, say BIO’s health policy experts. (682 words, 3 minutes, 24 seconds)
Read More